Anyone considering BPC-157 must understand they are exploring a research-stage compound with limited human safety data, not a proven medical treatment
The compound delivers predictable, well-characterized results across the full timeline, which makes planning and expectation management far more reliable than interventions where individual response is harder to anticipate
[Use of L-carnitine in hyperfunction of the thyroid gland]
The initiation of an SGLT2 inhibitor or a GLP-1 receptor agonist compared with a DPP-IV inhibitor was associated with lower CV events and death without increasing the overall incidence rate of severe safety outcomes, regardless of frailty status, Elisabetta Patorno, MD, DrPH , associate professor of medicine at Harvard Medical School and associate epidemiologist in the division of pharmacoepidemiology and pharmacoeconomics at Brigham and Womens Hospital, and colleagues wrote
Dehydration on GLP-1 medications is one of the common side effects people tend to overlook, so it's worth paying attention to your fluid intake right from the start of treatment
G., Chen, R., Thurber, K